| Sep 13 |
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
|
| Sep 12 |
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
|
| Sep 12 |
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
|
| Sep 12 |
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
|
| Sep 12 |
Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
|
| Sep 12 |
Fulcrum crashes as GSK-partnered lead program fails
|
| Sep 12 |
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
|
| Sep 10 |
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
|
| Sep 10 |
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
|
| Sep 9 |
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
|
